NCT05527821

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

An Exploratory Clinical Study of Short Course Radiotherapy Combined With Surufatinib and Sintilimab in the Treatment of Relapsed and Refractory Advanced Solid Tumors

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

An exploratory clinical study of short course radiotherapy combined with surufatinib and sintilimab in the treatment of relapsed and refractory advanced solid tumors

Conditions

• Unresectable Advanced Solid Tumors
• Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Surufatinib	Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle
DRUG	Sintilimab	Sintilimab 200mg will be intravenously administered on Day 1 of each cycle
RADIATION	Short course radiotherapy	5Gy\*5F short course radiotherapy will be delivered

Timeline

• Start date: 2022-09-30
• Primary completion: 2024-09-30
• Completion: 2025-09-30
• First posted: 2022-09-06
• Last updated: 2022-09-06

Locations

1 site across 1 country: China